Malik Kahook, MD
Glaucoma Specialist · Aurora, CONPI 1578537122
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $1,237,781 of the $1,343,570 with a category attached, or 92.1%. NEW World Medical,inc. accounts for 93.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $571,892 and has fallen 99.9% since, to $464 in 2025.
Across 134 payments — averaging $10,027 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$1.3M
- Alcon$58K
- Alcon Research LLC$19K
- AbbVie$10K
- Aerie Pharmaceuticals, Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- plus $237 from 2 others
Across 11 payments — averaging $2573.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$28K
Across 10 payments — averaging $105,097 each. An ownership or investment interest held by the physician or an immediate family member.
- NEW World Medical,inc.$1.1M
What the payments were for
- Consulting fees$29,1382%
- Travel & lodging$14,8471%
- Food & beverage$5,2910%
- Ownership interest$1,237,78192%
- Other$56,5134%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 83 | $1,252,712 |
| Alcon | 8 | $58,358 |
| Alcon Research LLC | 15 | $18,799 |
| AbbVie | 18 | $9,509 |
| Aerie Pharmaceuticals, Inc. | 3 | $2,190 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $1,766 |
| Carl Zeiss Meditec, Inc. | 3 | $134 |
| The Cameron-ehlen Group, Inc. | 1 | $103 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$1,243,357
- Kahook Dual Blade$1,243,357
- Streamline Surgical System$507,575
- Hydrus Microstent$56,513
- CyPass$3,420
- Rocklatan$2,099
- VYZULTA$1,715
- LUMIGAN$1,000
- XEN$1,000
- Clearpath$616
- Streamline$616
- AcrySof$505
- Via360$360
- Rhopressa$119
- Symfony IOL$103
- Healon OVD$103
- Toric IOL$103
- Zepto handpiece$103
- Phaco Tubing and Accessories$103
How this compares
Too few glaucoma specialist providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 47 | $30,114 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 43 | $14,487 |
| Latanoprost | 206 | $3,519 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $3,284 |
| Alphagan PBrimonidine Tartrate | 13 | $2,368 |
| Brimonidine Tartrate | 54 | $1,877 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 82 | $1,700 |
| Dorzolamide Hcl | 49 | $1,407 |
| Timolol Maleate | 21 | $212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $9,509 | $35,76571 claims |
| AlconSimbrinza | $58,358 | $14,48743 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Aurora
- Leonard SeiboldAurora$41K
- Monica ErtelAurora$7K
- Jeffrey SoohooAurora$5K
- Galia DeitzAurora$1K
- Cara Capitena YoungAurora$824
- Mina PantchevaAurora$719
- Meredith SpitzAurora$498
- Lama AssiAurora$71
- Stephanie MuylaertLittleton$17K
- Micah RothsteinLongmont$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.